在HFpEF中β抑制剂的潜在影响
Wojciech Tokarczyk1, Szymon Urban2, Patryk Patrzałek3
1Institute of Heart Diseases, University Hospital in Wrocław, Wrocław, Poland. wojciech.tokarczyk98@gmail.com.
Heart failure reviews
|December 3, 2024
概括
β-阻塞剂在心力衰竭中提供了不确定的好处,具有保存的喷射分数 (HFpEF). 需要更多的研究来澄清它们在HFpEF管理中的作用,并改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭带来了重大挑战,包括降低生活质量和增加死亡率.
- 目前对HFpEF的治疗策略有限,对β-阻断剂使用的指导不清楚.
研究的目的:
- 审查目前关于在患有HFpEF的患者中使用β抑制剂的证据.
- 为了确定知识上的差距和未来研究领域,关于β-阻断剂在HFpEF中的有效性.
主要方法:
- 对HFpEF中β抑制剂使用现有研究的文献综述.
- 分析潜在的益处和风险,包括对交感活动,慢性能力和运动耐受性的影响.
主要成果:
- β-阻断剂可能会降低交感活动,但可以加剧慢性无能症并降低HFpEF的运动耐受性.
- 关于临床终点的证据,包括死亡率和住院病例,仍然没有确定性.
- 潜在的好处可能会因射出分数子组而异 (例如,HFmrEF与HFpEF).
结论:
- 在HFpEF管理中β抑制剂的作用还不清楚.
- 大规模的随机临床试验对于制定明确的治疗指南至关重要.
- 需要进一步的研究来优化HFpEF的治疗方案.
相关概念视频
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
529
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
529
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Antihypertensive Drugs: Types of β-Blockers
582
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
582
Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K


